Pharmaceutical companies are undergoing a digital transformation. By experimenting with new initiatives, they are positioned to play a role in the revolution of healthcare. This transformation is driven by data from internal and external sources, including both -omic data and that from digital devices. Bio-IT World WEST, part of Molecular Medicine Tri-Conference, brings together all the stakeholders involved in this transformation. Your registration includes the option to track-hop to the other programs at the Molecular Med TRI-CON as well as the Hackathon, plenary keynote, exhibit/poster hall, and more!

Every facet of healthcare and medicine now generates and has access to enormous amounts of data from across sources, organizations, and the world. The pharmaceutical industry plays a key role in driving informatics for translational research and precision medicine. The 12th Annual Digitalization of Pharma R&D conference will discuss the challenges related to integrating, analyzing, and interpreting data from clinical trials, sequencing, electronic health records, and wearables. We will discuss informatics strategy for entire organizations from business goals to infrastructure and storage projects. Special attention will be paid to artificial intelligence, machine learning, natural language processing, and how companies are integrating these tools into their informatics infrastructure. Join informatics experts from pharma, biotech, and biomedical research communities to discuss these challenges and real-world examples of informatics projects driving precision medicine.

Final Agenda

Sunday, March 1

2:00 - 5:00 pm Afternoon Short Courses*

*Separate registration required

5:30 - 8:30 Dinner Short Courses*

*Separate registration required

Monday, March 2

8:00 - 11:00 am Morning Short Courses*

*Separate registration required

10:30 Conference Program Registration Open

KEYNOTE SESSION

(please see Keynote pages for details)

11:45 Organizer’s Opening Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

11:50 Chairperson’s Remarks

Allison Proffitt, Editorial Director, Bio-IT World

11:55 Keynote Sponsor Introduction (Sponsorship Opportunity Available)


12:10 pm KEYNOTE PRESENTATION: The AI Bubble and the Emerging Thinking Economy

Pietro Michelucci, PhD, Director, Human Computation Institute

12:40 KEYNOTE PANEL DISCUSSION: Data Quality in Human Computation Systems

Moderator: Allison Proffitt, Editorial Director, Bio-IT World

Panelists: Jennifer Couch, PhD, Chief, Structural Biology and Molecular Applications Branch, Division of Cancer Biology and Citizen Science Coordinator, National Cancer Institute

Devin Krotman, Director, Global Learning XPRIZE and IBM Watson AI XPRIZE

Vani Mandava, Director, Data Science Outreach, Microsoft Research

Pietro Michelucci, PhD, Director, Human Computation Institute

Ginger Tsueng, PhD, Scientific Outreach Project Manager, Department of Integrative, Structural and Computational Biology, The Scripps Research Institute

 

1:30 Bio-IT World WEST Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

2:05 Session Break

FEATURED SESSION: BUILDING A STRONG DATA FOUNDATION

2:20 Chairperson’s Remarks

Alan S. Louie, PhD, Research Director, Life Sciences, IDC Health Insights

2:25 Running Too Fast with AI, Pitfalls of Bad Data

Faisal Khan, PhD, Executive Director, Advanced Analytics and AI, AstraZeneca

The use of artificial intelligence and data science approaches and technologies is experiencing explosive growth in the pharmaceutical industry. The plethora of opportunities provide an exciting range of applications to explore. However, as the field has grown, many folks are employing and leveraging AI without keeping in mind the rigors required for good science, including preparing the data and how it’s analyzed. At the end of the data, it’s still garbage in/garbage out.

2:55 Building Data Science Teams for Pharma – Myths and Realities

Asif Jan, PhD, Group Director, PHC Data Science; Senior Director, Head of Data Science, Roche

It is hoped that combining real-world data with sophisticated statistical and machine learning algorithms could lead to realizing the dream of personalized healthcare. In order to make this dream a reality, data scientists need to embrace organizational data and methodological complexities not commonly encountered elsewhere. In this talk, the speaker would share his experiences in building data science teams ready to tackle the challenge of delivering personalized healthcare for everyone.

3:25 Leveraging Omics for Discovery and Development of New Drugs

Howard J. Jacob, PhD, Vice President and Head, Genomic Research, Drug Discovery Science & Technology, Distinguished Research Fellow, Abbvie

3:55 Sponsored Presentation (Opportunity Available)

4:25 Refreshment Break and Transition to Plenary Keynote


PLENARY KEYNOTE SESSION

4:35 Welcome Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

4:45 PLENARY KEYNOTE INTRODUCTION

Thomas Westerling-Bui, PhD, Senior Scientist, Regional Business Development, Aiforia

5:00 PLENARY KEYNOTE PRESENTATION: High-Performance Medicine

Eric Topol, MD, Founder and Director, Scripps Research Translational Institute (SRTI); Author, Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again

 

 

 

 

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

7:30 End of Day

Tuesday, March 3

7:30 am Registration Open and Morning Coffee

KEYNOTE SESSION

(please see Keynote pages for details)

8:00 Organizer’s Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

8:05 Chairperson’s Remarks

Sudeep Basu, PhD, Practice Leader, TechVision-Innovation Services, Frost & Sullivan

8:10 Keynote Sponsor Introduction

Vasu Rangadass, President, CEO, L7 Infromatics, Inc.

 


8:25 KEYNOTE PRESENTATION: AI and Big Data Strategies in Accelerating Clinical Research for Faster Rare Disease Cures

Harsha K. Rajasimha, MS, PhD, Founder, Jeeva Informatics Solutions, Inc.; Founder, Organization for Rare Diseases India–USA (ORDIUSA); Co-Director, Rare Diseases Systems Biology Initiative, George Mason University

8:55 KEYNOTE PANEL DISCUSSION: Applications of AI Technologies in Pharmaceuticals: Facilitating Development of Therapeutics in Treating Rare Diseases

Moderator: Sudeep Basu, PhD, Practice Leader, TechVision-Innovation Services, Frost & Sullivan

Panelists: Tom Defay, Senior Director, R&D Strategy and Alliances, SPMD, Strategy, Program Management and Data Sciences, Alexion

Annastasiah Mhaka, PhD, President, The Alliance for Artificial Intelligence in Healthcare (AAIH)

Harsha K. Rajasimha, MS, PhD, Founder, Jeeva Informatics Solutions, Inc.; Founder, Organization for Rare Diseases India–USA (ORDIUSA); Co-Director, Rare Diseases Systems Biology Initiative, George Mason University

Additional Panelists to be Announced

 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

WORK SMARTER (NOT HARDER) WITH YOUR DATA

10:40 Chairperson’s Remarks

Asif Jan, PhD, Group Director, PHC Data Science; Senior Director, Head of Data Science, Roche

10:45 Advancing the Use of Real World Data to Support R&D and Personalized Healthcare

Ryan Copping, PhD, Global Head of Analytics, PHC Data Science, Personalized Healthcare (PHC), Product Development, Roche & Genentech

Generating insights from Real World Data (RWD) is a critical success factor for personalized healthcare. This presentation will look at some of the advancements being made in terms of data (access/growth/quality/linkages, etc.), analytics and technology and will share some specific examples from Roche/Genentech’s R&D efforts as well some of the challenges and opportunities for the future.

11:15 CO-PRESENTATION: Target Identification and Drug Repurposing: From Machine Learning Theory to Practical Experience

Pankaj Agarwal, Chief Computational Biologist, BioInfi

Deepak Kumar Rajpal, PhD, Head, Bioinformatics, Translational Sciences, Sanofi

AI and Machine Learning are being widely used in drug discovery, yet there are significant challenges because of the lack of training examples in the biological data space. We will show three case studies examining the same problem from different angles and using different methods. You will see the limitations of each approach and how different validation schemes impact results.

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Session Break

12:20 Bio-IT World WEST Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

2:00 Breakout Discussions in the Exhibit Hall

3:00 Transition to Conference Programs

DATASETS TO IMPROVE MODELING

3:15 Chairperson’s Remarks

Eric Martin, PhD, Director, Computer Aided Drug Design, Novartis Institutes for BioMedical Research, Inc.

3:20 Massively Multitask Profile-QSAR: Applications of Experiment-Quality Models for >8500 Novartis Biochemical And Cellular Assays

Eric Martin, PhD, Director, Computer Aided Drug Design, Novartis Institutes for BioMedical Research, Inc.

Profile-QSAR predicts biological activity with unprecedented accuracy and applicability domain by combining 20 million IC50 measurements from 2 million compounds covering 12,000 assays. The 8600 “successful” models have average accuracy comparable to 4-concentration IC50 experiments. Models are updated monthly, storing 60 billion predictions for 5.5 million compounds in a databricks database. It has been applied to 150 projects for virtual screening, selectivity design, tox and MoA prediction, and more.

3:50 Machine Learning-Based Patient Subgroup Identification for Precision Medicine

Jie Cheng, PhD, Director, Exploratory Statistics, Abbvie

Central to precision medicine is the ability to detect patient subgroups with differential treatment effects in clinical trial datasets. These patient subgroups are defined by clinical variables and biomarkers. We will provide a brief overview of existing methods for patient subgroup identification and then present our novel approach. The performance of our method is evaluated against other state-of-the-art methods using both simulation and real-world clinical trial datasets.

4:20 Sponsored Presentation (Opportunity Available)

4:50 Spring Fling Celebration in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

6:00 End of Day

6:30 - 9:30 Dinner Short Courses*

*Separate registration required

Wednesday, March 4

6:45 am Registration Open

7:00 BREAKFAST PANEL DISCUSSION: The Time is NOW: Creating Meaningful Change for Women in the Workplace (Sponsorship Opportunity Available)

Moderator: Robin Toft, Author of WE CAN, The Executive Woman’s Guide to Career Advancement; Founder and Chairman, Toft Group Executive Search

Panelists: Camille Samuels, MBA, Partner, Venrock

Paul Hastings, President and CEO, Nkarta Therapeutics, Inc

Teresa L. Wright, MD, Staff Physician, Medicine, San Francisco Veterans Administration

KEYNOTE SESSION

(please see Keynote pages for details)

8:00 Organizer’s Remarks

Edel O’Regan, PhD, Vice President, Production, Cambridge Healthtech Institute

8:05 Chairperson’s Remarks

Joseph Ferrara, CEO, Boston Healthcare

8:10 Keynote Sponsor Introduction (Sponsorship Opportunity Available)


8:25 KEYNOTE PRESENTATION: The Value and Application of Informatics in Cancer Care Delivery

Debra A. Patt, MD, Vice President, Public Policy & Academic Affairs, Medical

Oncologist, Texas Oncology Cancer Center & Editor in Chief, Journal of Clinical Oncology-Clinical Cancer Informatics

8:55 KEYNOTE PANEL DISCUSSION: Pragmatic Use of Informatics in Cancer Care Delivery and Cancer Research: Big Data and AI Take on Cancer

Moderator: Joseph Ferrara, CEO, Boston Healthcare

Panelists: Mark Hulse, Chief Digital Officer, City of Hope

Debra A. Patt, MD, Vice President, Public Policy & Academic Affairs, Medical Oncologist, Texas Oncology Cancer Center & Editor in Chief, Journal of Clinical Oncology-Clinical Cancer Informatics

Nicholas Schork, PhD, Deputy Director of Quantitative Sciences, Distinguished Professor of Quantitative Medicine, The Translational Genomics Research Institute (TGen)

Robert P. Sebra, PhD, Associate Professor, Director of Technology Development & Genomics Core Facility, Icahn Institute, Icahn School of Medicine, Mount Sinai

Ajay Shah, PhD, Executive Director & Head of IT for Translational Medicine, Bristol-Myers Squibb

Paul A. Rejto, PhD, Vice President, Head of Translational Research, Pfizer Oncology R&D

 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

BUSINESS STRATEGY FOR PHARMA PIPELINES

10:40 Chairperson’s Remarks

Faisal Khan, PhD, Executive Director, Advanced Analytics and AI, AstraZeneca

10:45 CASE STUDY: Shaping Your Business Strategy with Advanced Analytics

Nuray Yurt, Executive Director, Enterprise Analytics & Data Science, Novartis

In this presentation you will: 1) learn of the roles that big data and advanced analytics can play in forecasting demand to refocus your product pipeline; 2) deliver results via management of your pipeline along with the risk factors associated with using AI & ML; and 3) understand the importance of end-to-end visibility and see how this can drive efficiency and operational excellence.

11:15 PANEL DISCUSSION: Partnering for AI Startups and Pharma

Topics to be Discussed:

  • Meeting expectations, what is good for both sides
  • How we can facilitate the transformation of pharma R&D
  • Best practices

Moderator: Harry Glorikian, General Partner, New Ventures Funds

Panelists to be Announced

12:00 pm PANEL DISCUSSION: Recruiting Data Scientists

Given the massive expansion of Data Science and the consequent need for experts in this area across all industries, there is a massive competition to find and source the talent required. How can we identify, recruit and retain the best data scientists? What are the pitfalls and challenges to avoid and success stories we can learn from?

Moderator: Faisal Khan, PhD, Executive Director, Advanced Analytics and AI, AstraZeneca

Panelists to be Announced

 

12:45 Session Break

12:50 Bio-IT World WEST Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing, Speed Networking, Book Signing, and Meetup Group

FEATURED SESSION: DATA STRATEGIES FOR GENOMICS

2:00 Chairperson’s Remarks

Zhaoshi Jiang, PhD, Executive Director of Bioinformatics & Clinical Data Sciences, Gilead Sciences

2:05 Fake It ‘til You Make It (Reproducible): Synthetic Data Resources for Genomics

Geraldine A. Van der Auwera, PhD, Director of Outreach and Communications, Data Sciences Platform, Broad Institute

The computational reproducibility of published biomedical research is limited by data access restrictions, affecting not just researchers who wish to reuse published analysis code, but also tool developers and educators who lack suitable example data for testing and training. We present: 1) a prototype pipeline that wraps established open-source data simulation tools to generate publicly shareable synthetic sequence data at any scale; and 2) a plan to develop community resources.

2:35 Progress in Diagnosing Rare Disease Patients Leveraging NLP and Genomic Sequencing

Tom Defay, Senior Director, R&D Strategy and Alliances, SPMD, Strategy, Program Management and Data Sciences, Alexion

Diagnosing patients with rare disease is challenging. Whole exome and whole genome sequencing have improved our diagnostic abilities but can still fall short due to our lack of understanding of which mutations are most likely to be the cause of disease. By combining phenotypic information automatically extracted from the patient’s EMR with a patient’s genome sequence, we have developed a system for prioritizing which mutations may be most significant and proposing possible diagnoses. Advances on this approach will be discussed.

3:05 Drug Targets with Genomic Support

J. Wade Davis, PhD, ACOS Research Fellow, Director, Computational Genomics, Genomics Research Center (GRC), AbbVie

3:35 Close of Conference